[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 21 of about 21
1. Javeri H, Arora R, Correa AM, Hofstetter WL, Lee JH, Liao Z, McAleer MF, Maru D, Bhutani MS, Swisher SG, Izzo JG, Ajani JA: Influence of induction chemotherapy and class of cytotoxics on pathologic response and survival after preoperative chemoradiation in patients with carcinoma of the esophagus. Cancer; 2008 Sep 15;113(6):1302-8
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Influence of induction chemotherapy and class of cytotoxics on pathologic response and survival after preoperative chemoradiation in patients with carcinoma of the esophagus.
  • BACKGROUND: Patients with localized esophageal cancer (LEC) have diverse outcomes (post-therapy pathologic response, disease-free survival [DFS], and overall survival [OS]) after preoperative chemoradiation (P-CTRT), dictated also by inherent molecular heterogeneity.
  • Whether the type of therapy influences the outcomes remains largely unanswered.
  • It is hypothesized that induction chemotherapy (IC) or the type of cytotoxics used would not influence patient outcomes.
  • Data were collected regarding age, sex, baseline clinical stage, location, type of cytotoxics, post-therapy pathology, DFS, and OS.
  • IC and the type of cytotoxics used were found to be correlated with DFS, OS, and post-therapy pathologic response.
  • The type of therapy appeared to have no influence on the outcome: IC versus no IC (P = .58) or platinol versus taxane versus platinol plus taxane (P = .63).
  • Similarly, the type of pathologic response was not found to be influenced by IC (P = .18) or the type of cytotoxics used (P = .42).
  • CONCLUSIONS: IC or the type of cytotoxics used with radiation for patients with LEC does not appear to influence OS, DFS, or the type of pathologic response after therapy, suggesting that a plateau has been reached.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Esophageal Neoplasms / drug therapy. Esophageal Neoplasms / radiotherapy. Preoperative Care
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / radiotherapy. Adenocarcinoma / secondary. Adenocarcinoma / surgery. Adult. Aged. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Carcinoma, Squamous Cell / secondary. Carcinoma, Squamous Cell / surgery. Cisplatin / therapeutic use. Cohort Studies. Combined Modality Therapy. Esophagectomy / methods. Female. Fluorouracil / therapeutic use. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / diagnosis. Neoplasm Recurrence, Local / therapy. Paclitaxel / therapeutic use. Remission Induction. Retrospective Studies. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 American Cancer Society.
  • (PMID = 18623381.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


2. Sivula A, Buskens CJ, van Rees BP, Haglund C, Offerhaus GJ, van Lanschot JJ, Ristimäki A: Prognostic role of cyclooxygenase-2 in neoadjuvant-treated patients with squamous cell carcinoma of the esophagus. Int J Cancer; 2005 Oct 10;116(6):903-8
MedlinePlus Health Information. consumer health - Esophageal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic role of cyclooxygenase-2 in neoadjuvant-treated patients with squamous cell carcinoma of the esophagus.
  • Based on our previous demonstration that elevated cyclooxygenase-2 (COX-2) expression is a prognostic factor for reduced survival in patients with adenocarcinoma of the esophagus, the aim of our study was to analyze the role of COX-2 expression in esophageal squamous cell carcinoma.
  • Eighty-one patients had not received any therapy before surgery whereas 36 patients received neoadjuvant chemotherapy as part of a randomized controlled trial.
  • In the patients who received no chemotherapy, COX-2 expression was low in 75% and high in 25% of the specimens.
  • In this patient group, high COX-2 expression associated with distal location of the tumor (p = 0.02), but did not correlate with any other clinicopathological parameter tested, including overall survival.
  • In the patient group who received neoadjuvant chemotherapy, postoperative COX-2 expression was low in 69% and high in 31%.
  • Our results show that the prognostic significance of COX-2 depends on the histological type of esophageal carcinoma and preoperative treatment of the patient.
  • In conclusion, COX-2 is not a prognostic marker in squamous cell carcinoma of the esophagus, but low COX-2 expression is associated with poor prognosis in the neoadjuvant-treated patients.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Esophageal Neoplasms / drug therapy. Prostaglandin-Endoperoxide Synthases / analysis
  • [MeSH-minor] Biomarkers, Tumor / analysis. Cyclooxygenase 2. Female. Gastrectomy. History, 17th Century. Humans. Male. Membrane Proteins. Neoadjuvant Therapy. Neoplasm Invasiveness. Neoplasm Metastasis. Prognosis. Survival Analysis

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15856454.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Historical Article; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Membrane Proteins; EC 1.14.99.1 / Cyclooxygenase 2; EC 1.14.99.1 / PTGS2 protein, human; EC 1.14.99.1 / Prostaglandin-Endoperoxide Synthases
  •  go-up   go-down


3. Rohatgi P, Swisher SG, Correa AM, Wu TT, Liao Z, Komaki R, Walsh GL, Vaporciyan AA, Rice DC, Roth JA, Ajani JA: Characterization of pathologic complete response after preoperative chemoradiotherapy in carcinoma of the esophagus and outcome after pathologic complete response. Cancer; 2005 Dec 1;104(11):2365-72
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characterization of pathologic complete response after preoperative chemoradiotherapy in carcinoma of the esophagus and outcome after pathologic complete response.
  • BACKGROUND: The purpose of the current study was to test the hypothesis that a lower clinical TNM stage is associated with a higher rate of pathologic complete response (pathCR) in patients with esophageal carcinoma receiving preoperative chemoradiotherapy and to determine whether outcome after pathCR is related to clinical stage or treatment.
  • The proportion of patients who received induction chemotherapy was higher in the pathCR group than in the <pathCR group (54% vs. 46%; P = 0.05).
  • However, neither TNM classification, primary tumor location, histologic type, gender, therapy sequence, or radiation dose (45 grays [Gy] vs. 50.4 Gy) were found to have any influence on OS or DFS.
  • Chemoradiotherapy as primary therapy for patients with Stage I esophageal carcinoma warrants investigation as a means to preserve their esophagus.
  • [MeSH-major] Esophageal Neoplasms / drug therapy. Esophageal Neoplasms / radiotherapy
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / pathology. Adenocarcinoma / radiotherapy. Adult. Aged. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / radiotherapy. Female. Humans. Male. Middle Aged. Neoplasm Staging. Predictive Value of Tests. Retrospective Studies. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16245310.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


Advertisement
4. Samadi F, Babaei M, Yazdanbod A, Fallah M, Nouraie M, Nasrollahzadeh D, Sadjadi A, Derakhshan MH, Shokuhi B, Fuladi R, Malekzadeh R: Survival rate of gastric and esophageal cancers in Ardabil province, North-West of Iran. Arch Iran Med; 2007 Jan;10(1):32-7
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: A prospective follow-up study of 420 biopsy-proven patients (127 females, mean age: 64) with upper gastrointestinal cancer (141 esophageal and 279 stomach cancers) who were initially diagnosed in Aras Clinic, the main gastrointestinal referral center of Ardabil Province, from 2000 through 2004, was performed with collection of data on demographics, tumor characteristics, pathologic stage, treatment methods, complications, survival time, etc.
  • Follow-up was from cancer diagnosis until death, or immigration.
  • Survival according to stage of disease, Lauren tumor type, tumor location, surgery, and adjuvant chemotherapy was analyzed, and results were compared with those of western series.
  • Patients who had undergone surgery (P < 0.001) and/or chemotherapy (P < 0.001) survived longer than those without such treatments.
  • Tumor morphology, age at diagnosis, radiotherapy, alcohol, and opium consumption did not show any significant effects on the survival rate of patients.
  • CONCLUSION: Survival rate of stomach and esophagus cancer cases in Ardabil is relatively low.
  • Intervention for early detection and therapy is necessary to increase survival.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biopsy. Female. Follow-Up Studies. Humans. Iran / epidemiology. Male. Middle Aged. Neoplasm Staging. Prognosis. Prospective Studies. Sex Distribution. Survival Rate / trends

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Rural Health Concerns.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17198451.001).
  • [ISSN] 1029-2977
  • [Journal-full-title] Archives of Iranian medicine
  • [ISO-abbreviation] Arch Iran Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Iran
  •  go-up   go-down


5. Kutter J, Ozsahin M, Monnier P, Stupp R: Combined modality treatment with full-dose chemotherapy and concomitant boost radiotherapy for advanced head and neck carcinoma. Eur Arch Otorhinolaryngol; 2005 Jan;262(1):1-7
Hazardous Substances Data Bank. AMIFOSTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combined modality treatment with full-dose chemotherapy and concomitant boost radiotherapy for advanced head and neck carcinoma.
  • The purpose of this study was to evaluate the feasibility and efficacy of a treatment concept combining three cycles of full-dose chemotherapy (CT) with concomitant accelerated uninterrupted radiotherapy (RT).
  • The primary tumor involved the hypopharynx (n=7), base of the tongue (n=10), nasopharynx (n=2) or upper esophagus (n=1) or its location was unknown (n=3).
  • Treatment consisted of three cycles of chemotherapy (cisplatin 100 mg/m2 on day 1; 5-FU 1,000 mg/m2 per day for 5 days as a continuous infusion, preceded by amifostine 910 mg/m2), repeated every 3 weeks.
  • Uninterrupted concomitant boost-accelerated RT (total dose of 70 Gy in 6 weeks) started together on day 1 of the second cycle.
  • Concomitant boost-accelerated RT combined with concurrent full-dose cisplatin/5-FU chemotherapy and amifostine is feasible with manageable, although substantial, toxicity.
  • [MeSH-major] Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Esophageal Neoplasms / drug therapy. Esophageal Neoplasms / radiotherapy. Hypopharyngeal Neoplasms / drug therapy. Hypopharyngeal Neoplasms / radiotherapy. Nasopharyngeal Neoplasms / drug therapy. Nasopharyngeal Neoplasms / radiotherapy. Tongue Neoplasms / drug therapy. Tongue Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Amifostine / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cisplatin / therapeutic use. Combined Modality Therapy. Drug Administration Schedule. Female. Humans. Male. Middle Aged. Neoplasm Staging. Radiotherapy Dosage

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Natl Cancer Inst. 1996 May 1;88(9):583-9 [8609658.001]
  • [Cites] N Engl J Med. 1998 Jun 18;338(25):1798-804 [9632446.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1992;23(2):457-67 [1534082.001]
  • [Cites] Lancet. 2000 Mar 18;355(9208):949-55 [10768432.001]
  • [Cites] Rays. 2000 Jul-Sep;25(3):313-9 [11367896.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1987 Jan;13(1):41-7 [3542916.001]
  • [Cites] Support Care Cancer. 2002 Sep;10(6):502-4 [12353130.001]
  • [Cites] N Engl J Med. 1992 Oct 15;327(16):1115-21 [1302472.001]
  • [Cites] J Clin Oncol. 1996 Jul;14(7):2101-12 [8683243.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1990 Dec;19(6):1347-50 [2262356.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2002 Feb;128(2):181-6 [11843728.001]
  • [Cites] Semin Surg Oncol. 2001 Jan-Feb;20(1):66-74 [11291134.001]
  • [Cites] Ann Oncol. 1999 Jun;10(6):693-700 [10442192.001]
  • [Cites] Cancer. 2000 Sep 1;89(5):939-45 [10964322.001]
  • [Cites] Semin Oncol. 1999 Apr;26(2 Suppl 7):95-101 [10348267.001]
  • [Cites] J Clin Oncol. 1998 Apr;16(4):1318-24 [9552032.001]
  • [Cites] Head Neck. 2001 Sep;23(9):713-7 [11505479.001]
  • [Cites] Head Neck. 2001 Jul;23(7):579-89 [11400247.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Aug 1;48(1):7-16 [10924966.001]
  • [Cites] Otolaryngol Head Neck Surg. 2001 May;124(5):561-9 [11337663.001]
  • [Cites] Ann Oncol. 1998 May;9(5):505-9 [9653491.001]
  • [Cites] Cancer. 2001 Dec 1;92(11):2856-67 [11753959.001]
  • [Cites] Radiother Oncol. 2001 Aug;60(2):113-22 [11439206.001]
  • [Cites] J Natl Cancer Inst. 1996 Jul 3;88(13):890-9 [8656441.001]
  • [Cites] J Clin Oncol. 2000 Oct 1;18(19):3339-45 [11013273.001]
  • [Cites] BJR Suppl. 1992;24:200-3 [1290701.001]
  • [Cites] N Engl J Med. 1991 Jun 13;324(24):1685-90 [2034244.001]
  • [Cites] Head Neck. 2000 Oct;22(7):680-6 [11002323.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1992;23(4):705-13 [1618662.001]
  • [Cites] Bull Cancer Radiother. 1996;83(4):314-20 [9081333.001]
  • [Cites] Radiother Oncol. 1994 Feb;30(2):109-20 [8184108.001]
  • [Cites] Laryngoscope. 1988 Nov;98(11):1205-11 [3054373.001]
  • [Cites] Head Neck. 1997 Sep;19(6):500-5 [9278758.001]
  • [Cites] Head Neck. 1998 Sep;20(6):489-96 [9702534.001]
  • [Cites] J Clin Oncol. 1990 May;8(5):911-34 [2185342.001]
  • [Cites] Radiother Oncol. 1997 Apr;43(1):47-51 [9165136.001]
  • [Cites] Radiother Oncol. 1992 Dec;25(4):231-41 [1480768.001]
  • [Cites] J Clin Oncol. 1991 Aug;9(8):1376-84 [2072141.001]
  • [Cites] Strahlenther Onkol. 1995 Mar;171(3):140-8 [7535952.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Mar 15;46(5):1105-8 [10725619.001]
  • [Cites] J Natl Cancer Inst. 1994 Feb 16;86(4):265-72 [8158680.001]
  • [Cites] Cancer. 1987 Aug 1;60(3):301-11 [2885080.001]
  • [Cites] J Clin Oncol. 1994 Sep;12(9):1876-85 [8083711.001]
  • [Cites] Head Neck. 2001 May;23(5):353-62 [11295808.001]
  • [Cites] Cancer. 2000 Feb 15;88(4):876-83 [10679658.001]
  • [Cites] Head Neck. 1997 Oct;19(7):567-75 [9323144.001]
  • (PMID = 15004704.001).
  • [ISSN] 0937-4477
  • [Journal-full-title] European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery
  • [ISO-abbreviation] Eur Arch Otorhinolaryngol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] M487QF2F4V / Amifostine; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


6. Hagen JA, DeMeester SR, Peters JH, Chandrasoma P, DeMeester TR: Curative resection for esophageal adenocarcinoma: analysis of 100 en bloc esophagectomies. Ann Surg; 2001 Oct;234(4):520-30; discussion 530-1
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • No patient received pre- or postoperative chemotherapy or radiation therapy.
  • Tumor depth and number and location of involved lymph nodes were recorded.
  • CONCLUSION: Long-term survival from adenocarcinoma of the esophagus can be achieved in more than half the patients who undergo en bloc resection.
  • [MeSH-minor] Adult. Aged. Biopsy, Needle. Disease-Free Survival. Esophagoscopy. Female. Follow-Up Studies. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasm Staging. Postoperative Complications / mortality. Probability. Statistics, Nonparametric. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Thorac Cardiovasc Surg. 1988 Aug;96(2):242-8 [2456424.001]
  • [Cites] Ann Surg. 1984 Sep;200(3):282-8 [6465981.001]
  • [Cites] J Surg Oncol. 1993 Apr;52(4):231-5 [8468984.001]
  • [Cites] JAMA. 1993 Sep 15;270(11):1320 [8360967.001]
  • [Cites] J Thorac Cardiovasc Surg. 1993 Nov;106(5):850-8; discussion 858-9 [8231207.001]
  • [Cites] J Am Coll Surg. 1994 Jan;178(1):83-5 [8156125.001]
  • [Cites] Br J Surg. 1994 Mar;81(3):404-7 [8173913.001]
  • [Cites] Br J Surg. 1994 Mar;81(3):410-3 [8173915.001]
  • [Cites] Hepatogastroenterology. 1994 Aug;41(4):391-3 [7959579.001]
  • [Cites] Ann Thorac Surg. 1994 Nov;58(5):1569-70 [7979715.001]
  • [Cites] Ann Thorac Surg. 1995 Oct;60(4):896-901; discussion 902 [7574991.001]
  • [Cites] Ann Surg. 1995 Nov;222(5):654-62 [7487213.001]
  • [Cites] Surgery. 1995 Nov;118(5):845-55 [7482272.001]
  • [Cites] N Engl J Med. 1996 Aug 15;335(7):462-7 [8672151.001]
  • [Cites] Am J Surg. 1996 Nov;172(5):478-81; discussion 481-2 [8942548.001]
  • [Cites] Gut. 1997 Jan;40(1):123-7 [9155589.001]
  • [Cites] Cancer. 1982 Dec 1;50(11 Suppl):2571-5 [7139552.001]
  • [Cites] Ann Surg. 1981 Oct;194(4):438-46 [7283505.001]
  • [Cites] Hum Pathol. 1986 May;17(5):482-7 [3699811.001]
  • [Cites] Ann Surg. 1986 Oct;204(4):391-401 [2429625.001]
  • [Cites] Ann Thorac Surg. 1987 Aug;44(2):119-22 [3619535.001]
  • [Cites] J Thorac Cardiovasc Surg. 1997 May;113(5):836-46; discussion 846-8 [9159617.001]
  • [Cites] N Engl J Med. 1997 Jul 17;337(3):161-7 [9219702.001]
  • [Cites] J Thorac Cardiovasc Surg. 1997 Aug;114(2):205-9 [9270637.001]
  • [Cites] World J Surg. 1997 Oct;21(8):822-31 [9327673.001]
  • [Cites] J Thorac Cardiovasc Surg. 1997 Dec;114(6):948-55; discussion 955-6 [9434690.001]
  • [Cites] Ann Thorac Surg. 1998 Mar;65(3):787-92 [9527214.001]
  • [Cites] J Thorac Cardiovasc Surg. 1998 Mar;115(3):660-69; discussion 669-70 [9535455.001]
  • [Cites] N Engl J Med. 1998 Dec 31;339(27):1979-84 [9869669.001]
  • [Cites] J Thorac Cardiovasc Surg. 1999 Jan;117(1):16-23; discussion 23-5 [9869753.001]
  • [Cites] Cancer Radiother. 1998 Dec;2(6):763-70 [9922785.001]
  • [Cites] Lancet. 1999 Sep 4;354(9181):792-4 [10485718.001]
  • [Cites] Ann Surg. 1999 Sep;230(3):433-8; discussion 438-40 [10493489.001]
  • [Cites] J Am Coll Surg. 2000 Aug;191(2):143-8 [10945357.001]
  • [Cites] J Clin Oncol. 2001 Jan 15;19(2):305-13 [11208820.001]
  • [Cites] World J Surg. 1992 Nov-Dec;16(6):1104-9; discussion 1110 [1455880.001]
  • (PMID = 11573045.001).
  • [ISSN] 0003-4932
  • [Journal-full-title] Annals of surgery
  • [ISO-abbreviation] Ann. Surg.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC1422075
  •  go-up   go-down


7. Yoon HH, Khan M, Shi Q, Cassivi SD, Wu TT, Quevedo JF, Burch PA, Sinicrope FA, Diasio RB: The prognostic value of clinical and pathologic factors in esophageal adenocarcinoma: a mayo cohort of 796 patients with extended follow-up after surgical resection. Mayo Clin Proc; 2010 Dec;85(12):1080-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PATIENTS AND METHODS: The study cohort consisted of 796 patients with adenocarcinoma of the esophagus, gastroesophageal junction, or gastric cardia who underwent complete tumor resection at Mayo Clinic from January 1, 1980, to December 31, 1997.
  • The following factors remained significantly linked with worse 5-year disease-specific survival on multivariate analysis: higher N and T status, grade, and age and the absence of preoperative chemotherapy or radiotherapy.
  • Anatomic location of tumor was not associated with differential prognosis.

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg. 2007 Dec;246(6):992-1000; discussion 1000-1 [18043101.001]
  • [Cites] J Natl Cancer Inst. 2008 Aug 20;100(16):1184-7 [18695138.001]
  • [Cites] Ann Surg Oncol. 2008 Nov;15(11):3278-88 [18726651.001]
  • [Cites] J Thorac Cardiovasc Surg. 2001 Mar;121(3):454-64 [11241080.001]
  • [Cites] Ann Surg Oncol. 2002 Mar;9(2):210-4 [11888881.001]
  • [Cites] Nature. 2002 Aug 22;418(6900):823 [12192390.001]
  • [Cites] Cancer. 2002 Oct 1;95(7):1434-43 [12237911.001]
  • [Cites] J Thorac Cardiovasc Surg. 2003 May;125(5):1103-13 [12771884.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Jul 15;56(4):981-7 [12829133.001]
  • [Cites] Eur J Surg Oncol. 2003 Aug;29(6):506-10 [12875856.001]
  • [Cites] N Engl J Med. 2003 Dec 4;349(23):2241-52 [14657432.001]
  • [Cites] J Am Coll Surg. 2004 Feb;198(2):205-11 [14759776.001]
  • [Cites] Surgery. 1995 Nov;118(5):845-55 [7482272.001]
  • [Cites] Ann Thorac Surg. 1997 May;63(5):1423-7 [9146337.001]
  • [Cites] Am J Surg. 1997 Sep;174(3):320-4 [9324146.001]
  • [Cites] Eur J Cardiothorac Surg. 1997 Sep;12(3):361-4; discussion 364-5 [9332912.001]
  • [Cites] Ann Thorac Surg. 1998 Mar;65(3):787-92 [9527214.001]
  • [Cites] J Am Coll Surg. 1998 Oct;187(4):345-51 [9783779.001]
  • [Cites] J Thorac Cardiovasc Surg. 1999 Jan;117(1):16-23; discussion 23-5 [9869753.001]
  • [Cites] Br J Surg. 2004 Dec;91(12):1586-91 [15505868.001]
  • [Cites] Am Surg. 2004 Nov;70(11):954-8 [15586504.001]
  • [Cites] J Natl Cancer Inst. 2005 Jan 19;97(2):142-6 [15657344.001]
  • [Cites] Clin Cancer Res. 2005 Mar 15;11(6):2229-36 [15788671.001]
  • [Cites] Virchows Arch. 2005 May;446(5):497-504 [15838647.001]
  • [Cites] Am J Surg Pathol. 2006 Feb;30(2):171-6 [16434890.001]
  • [Cites] J Clin Oncol. 2006 Sep 10;24(26):4347-55 [16963732.001]
  • [Cites] Surg Oncol Clin N Am. 2006 Oct;15(4):751-64 [17030271.001]
  • [Cites] CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66 [17237035.001]
  • [Cites] Lancet Oncol. 2007 Mar;8(3):226-34 [17329193.001]
  • [Cites] Curr Oncol Rep. 2007 May;9(3):184-92 [17430689.001]
  • [Cites] J Clin Oncol. 2007 Aug 20;25(24):3719-25 [17704421.001]
  • [Cites] Dis Esophagus. 2009;22(1):1-8 [19196264.001]
  • [Cites] Ann Thorac Surg. 2009 Apr;87(4):1048-54; discussion 1054-5 [19324126.001]
  • [Cites] Gastroenterol Clin North Am. 2009 Mar;38(1):27-57, vii [19327566.001]
  • [Cites] Gastroenterol Clin North Am. 2009 Mar;38(1):169-81, x [19327574.001]
  • [Cites] Hepatogastroenterology. 2009 May-Jun;56(91-92):707-10 [19621686.001]
  • [Cites] Cancer. 2009 Oct 1;115(19):4450-8 [19562780.001]
  • [Cites] J Clin Oncol. 2009 Oct 20;27(30):5062-7 [19770374.001]
  • [Cites] Nat Rev Cancer. 2010 Feb;10(2):87-101 [20094044.001]
  • [Cites] Cancer. 2010 Aug 15;116(16):3763-73 [20564099.001]
  • (PMID = 21123634.001).
  • [ISSN] 1942-5546
  • [Journal-full-title] Mayo Clinic proceedings
  • [ISO-abbreviation] Mayo Clin. Proc.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / K12CA90628-10U
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2996151
  •  go-up   go-down


8. Valentí V, Fares S, Reynolds N, Cohen P, Theodoro N, Martínez-Isla A: [Open and laparoscopic transhiatal oesophagectomy for cancer of the oesophagus: analysis of resection margins and lymph nodes]. Cir Esp; 2008 Jan;83(1):24-7
MedlinePlus Health Information. consumer health - Esophageal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTRODUCTION: Surgical treatment of cancer of the oesophagus is associated with a high morbidity and mortality.
  • Minimally invasive surgery has been proposed as an alternative to try to reduce these complications; however, at this time there are not many studies that evaluate the oncological validity of this method.
  • MATERIAL AND METHOD: Between April 2003 and February 2007, 40 patients diagnosed with distal oesophageal cancer were surgically intervened at Charing Cross Hospital, London, 24 open and 16 by laparoscopy in accordance with the surgeon responsible.
  • Of these, 50% received neoadjuvant chemotherapy.
  • Both groups were homogeneous for age, sex, ASA, tumour stage and tumour location.
  • In all cases, the pathological tumour stage (TNM), the tumour distal margin, tumour proximal margin, tumour circumference and number of resected lymph nodes, were collected in a data base.
  • The mean distal tumour margin for the group treated by open surgery was 4.9 cm compared to 4.3 in the group treated by laparoscopy (p = 0.578).
  • [MeSH-minor] Aged. Aged, 80 and over. Chemotherapy, Adjuvant. Data Interpretation, Statistical. Esophagus / pathology. Female. Humans. Male. Middle Aged. Minimally Invasive Surgical Procedures. Neoplasm Staging. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Cir Esp. 2008 Dec;84(6):295. Fares, Rally [corrected to Fares, Sally]
  • (PMID = 18208745.001).
  • [ISSN] 0009-739X
  • [Journal-full-title] Cirugía española
  • [ISO-abbreviation] Cir Esp
  • [Language] spa
  • [Publication-type] Comparative Study; English Abstract; Evaluation Studies; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


9. Ajani JA, Komaki R, Putnam JB, Walsh G, Nesbitt J, Pisters PW, Lynch PM, Vaporciyan A, Smythe R, Lahoti S, Raijman I, Swisher S, Martin FD, Roth JA: A three-step strategy of induction chemotherapy then chemoradiation followed by surgery in patients with potentially resectable carcinoma of the esophagus or gastroesophageal junction. Cancer; 2001 Jul 15;92(2):279-86
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A three-step strategy of induction chemotherapy then chemoradiation followed by surgery in patients with potentially resectable carcinoma of the esophagus or gastroesophageal junction.
  • BACKGROUND: Patients with locoregional carcinoma of the esophagus or gastroesophageal junction have a poor survival rate after surgery.
  • Preoperative chemotherapy or chemoradiotherapy has not improved the outcome for these patients.
  • Our study was designed to assess the feasibility of preoperative induction combination chemotherapy in addition to chemoradiotherapy to improve the curative resection rate, local control, and survival.
  • PATIENTS AND METHODS Patients having histologic proof of localized carcinoma (either squamous cell carcinoma or adenocarcinoma) of the esophagus or gastroesophageal junction underwent full classification including endoscopic ultrasonography (EUS).
  • Patients first received up to two courses of induction chemotherapy consisting of 5-fluorouracil at 750 mg/m(2)/day as continuous infusion on Days 1--5, cisplatin at 15 mg/m(2)/day as an intravenous bolus on Days 1--5, and paclitaxel at 200 mg/m(2) as a 24-hour intravenous infusion on Day 1.
  • Adenocarcinoma and distal esophageal location of carcinoma were observed frequently.
  • CONCLUSIONS: These data show that the three-step strategy of preoperative paclitaxel-based induction chemotherapy then chemoradiotherapy followed by surgery is feasible and appears quite active in patients having locoregional carcinoma of the esophagus or gastroesophageal junction.
  • Future investigations should focus on substituting cisplatin with less toxic agents and including more systemic therapy with newer classes of agents.
  • [MeSH-major] Adenocarcinoma. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell. Esophageal Neoplasms. Esophagogastric Junction / pathology. Stomach Neoplasms
  • [MeSH-minor] Adult. Aged. Cisplatin / administration & dosage. Combined Modality Therapy. Female. Fluorouracil / administration & dosage. Humans. Infusions, Intravenous. Injections, Intravenous. Male. Middle Aged. Neoadjuvant Therapy. Neoplasm Recurrence, Local. Paclitaxel / administration & dosage. Preoperative Care. Prognosis. Survival Analysis

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 American Cancer Society.
  • (PMID = 11466680.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


10. Theisen J, Stein HJ, Feith M, Kauer WK, Dittler HJ, Pirchi D, Siewert JR: Preferred location for the development of esophageal adenocarcinoma within a segment of intestinal metaplasia. Surg Endosc; 2006 Feb;20(2):235-8
MedlinePlus Health Information. consumer health - Esophageal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preferred location for the development of esophageal adenocarcinoma within a segment of intestinal metaplasia.
  • These patients received neoadjuvant chemotherapy.
  • The frequency of intestinal metaplasia and the location of the tumor occurrence within the segment of intestinal metaplasia were assessed.
  • RESULTS: Intestinal metaplasia was found in 83% of the early lesions and in 98% of the advanced tumors after neoadjuvant chemotherapy.
  • In 82.2% of the cases, the tumor was located at the distal margin of the intestinal metaplasia in patients with early tumor manifestations.
  • The remaining tumor mass after neoadjuvant therapy also was located predominantly at the distal margin of the segment of intestinal metaplasia (85% of the cases).
  • CONCLUSIONS: The results demonstrate that almost all adenocarcinomas of the esophagus are based on the development of a segment of intestinal metaplasia.
  • The distal margin of Barrett's mucosa seems to be the most vulnerable location for the development of invasive cancer.
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biopsy. Endoscopy, Gastrointestinal. Female. Humans. Intestinal Mucosa / pathology. Male. Metaplasia. Middle Aged. Neoadjuvant Therapy. Neoplasm Invasiveness / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Invest. 1996 Nov 1;98(9):2120-8 [8903332.001]
  • [Cites] Ann Surg. 2000 Dec;232(6):733-42 [11088068.001]
  • [Cites] Gut. 2003 Jan;52(1):24-7 [12477754.001]
  • [Cites] Gastroenterology. 1988 Jan;94(1):81-90 [3335302.001]
  • [Cites] Gastroenterology. 1989 May;96(5 Pt 1):1249-56 [2703113.001]
  • [Cites] Surg Endosc. 2002 Apr;16(4):671-3 [11972212.001]
  • [Cites] Gut. 1992 Nov;33(11):1454-8 [1452066.001]
  • [Cites] N Engl J Med. 1986 Aug 7;315(6):362-71 [2874485.001]
  • [Cites] Gastroenterol Clin North Am. 1997 Sep;26(3):507-17 [9309401.001]
  • [Cites] Chest Surg Clin N Am. 1994 May;4(2):217-25 [8049992.001]
  • [Cites] Eur J Gastroenterol Hepatol. 2000 Jun;12(6):649-54 [10912484.001]
  • [Cites] J Thorac Cardiovasc Surg. 1993 Jan;105(1):107-11 [8419690.001]
  • [Cites] Hepatogastroenterology. 1999 Jan-Feb;46(25):66-73 [10228767.001]
  • [Cites] Gut. 2003 Jan;52(1):28-33 [12477755.001]
  • [Cites] J Thorac Cardiovasc Surg. 1994 Nov;108(5):813-21; discussion 821-2 [7967662.001]
  • [Cites] Gastrointest Endosc. 2000 May;51(5):560-8 [10805842.001]
  • [Cites] Chest. 1997 Oct;112(4 Suppl):195S-200S [9337287.001]
  • [Cites] Chest. 1999 Dec;116(6 Suppl):466S-469S [10619510.001]
  • [Cites] Br J Surg. 1998 Nov;85(11):1457-9 [9823902.001]
  • [Cites] Gastroenterology. 2000 Sep;119(3):677-82 [10982761.001]
  • [Cites] Am J Med. 2001 Jul;111(1):33-7 [11448658.001]
  • [Cites] Arch Intern Med. 1991 Nov;151(11):2212-6 [1953225.001]
  • [Cites] Am J Gastroenterol. 1999 Aug;94(8):2037-42 [10445525.001]
  • [Cites] BMJ. 2000 Nov 18;321(7271):1252-5 [11082084.001]
  • [Cites] Ann Surg. 2000 Mar;231(3):303-21 [10714623.001]
  • [Cites] N Engl J Med. 1985 Oct 3;313(14):857-9 [4033716.001]
  • [Cites] Ann Surg. 2000 Sep;232(3):353-61 [10973385.001]
  • (PMID = 16391958.001).
  • [ISSN] 1432-2218
  • [Journal-full-title] Surgical endoscopy
  • [ISO-abbreviation] Surg Endosc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


11. Adham M, Baulieux J, Mornex F, de La Roche de Bransat E, Ducerf C, Souquet JC, Gerard JP: Combined chemotherapy and radiotherapy followed by surgery in the treatment of patients with squamous cell carcinoma of the esophagus. Cancer; 2000 Sep 1;89(5):946-54
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combined chemotherapy and radiotherapy followed by surgery in the treatment of patients with squamous cell carcinoma of the esophagus.
  • BACKGROUND: Surgery remains the treatment of choice for patients with esophageal squamous cell carcinoma (SCC), but survival rates have not improved over the past decades.
  • The objective of this study was to evaluate the effect of multimodal therapy on resectability, on the overall and on disease free survival (DFS) rates, and on the laryngeal resection rate.
  • METHODS: Fifty-five patients (49 men and 6 women) with a mean age of 58 +/- 8 years underwent combined modality treatment for esophageal SCC.
  • The tumor location was in the upper one-third of the esophagus in 19 patients, the middle one-third in 22 patients, the lower one-third in 9 patients, and the upper and lower one-thirds in 5 patients.
  • The intent of combined therapy was curative in 87.3% of patients and palliative in 12.7% of patients.
  • Neoadjuvant treatment consisted of two courses of 5-fluorouracil and cisplatin on Days 1-5 and Days 21-25.
  • RESULTS: Full neoadjuvant treatment was possible in 67.3% of patients and was uneventful in 56.
  • CONCLUSIONS: Neoadjuvant treatment is tolerated well by most patients.
  • Combination therapy increases the resectability rate and facilitates laryngeal preservation.
  • [MeSH-major] Carcinoma, Squamous Cell / therapy. Esophageal Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Disease-Free Survival. Female. Humans. Larynx / surgery. Male. Middle Aged. Neoplasm Staging. Postoperative Complications. Survival Rate. Treatment Outcome


12. Johansson J, DeMeester TR, Hagen JA, DeMeester SR, Peters JH, Oberg S, Bremner CG: En bloc vs transhiatal esophagectomy for stage T3 N1 adenocarcinoma of the distal esophagus. Arch Surg; 2004 Jun;139(6):627-31; discussion 631-3
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] En bloc vs transhiatal esophagectomy for stage T3 N1 adenocarcinoma of the distal esophagus.
  • PATIENTS: There were 49 patients (27 who underwent EBE and 22 who underwent THE) with similar T3 N1 disease and the following matched criteria: tumors of similar size and location, more than 20 lymph nodes in the surgical specimen, R0 resection, no previous chemotherapy or radiation therapy, and follow-up until death or for a minimum of 5 years.
  • The only 2 independent factors that affected survival in a Cox analysis were the number of involved lymph nodes (P =.01) and the type of resection (P =.03).
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Neoplasm Staging. Retrospective Studies. Survival Analysis

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15197089.001).
  • [ISSN] 0004-0010
  • [Journal-full-title] Archives of surgery (Chicago, Ill. : 1960)
  • [ISO-abbreviation] Arch Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


13. Stein HJ, Feith M, Siewert JR: Individualized surgical strategies for cancer of the esophagogastric junction. Ann Chir Gynaecol; 2000;89(3):191-8
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Due to their borderline location between the stomach and esophagus the optimal surgical strategy for patients with adenocarcinoma of the esophagogastric junction is controversial.
  • Irrespective of the surgical approach a complete removal of the primary tumor and its lymphatic drainage has to be the primary goal of surgical treatment of such tumors.
  • Based on the experience with surgical resection of more than 1000 patients with adenocarcinoma of the esophagogastric junction we recommend an individualized surgical strategy guided by tumor stage and topographic location of the tumor center or tumor mass.
  • This requires detailed preoperative staging and classification of tumors arising in the vicinity of the esophagogastric junction into adenocarcinoma of the distal esophagus (AEG Type I Tumors), true carcinoma of the gastric cardia (AEG Type II Tumors) and subcardial gastric carcinoma infiltrating the esophagogastric junction (AEG Type III Tumors).
  • In patients with Type I Tumors transthoracic esophagectomy offers no survival benefit over radical transmediastinal esophagectomy, but is associated with higher morbidity.
  • In patients with Type II or Type III tumors an extended total gastrectomy results in equal or superior survival and less postoperative mortality than a more extended esophagogastrectomy.
  • In patients with early tumors, staged as uT1 on preoperative endosonography, a limited resection of the proximal stomach, cardia and distal esophagus with interposition of a pedicled isoperistaltic jejunal segment allows a complete tumor removal with adequate lymphadenectomy and offers excellent functional results.
  • Multimodal treatment protocols with neoadjuvant chemotherapy or combined radiochemotherapy followed by surgical resection appear to markedly improve the prognosis in patients with locally advanced tumors who respond to preoperative treatment.
  • With this tailored approach extensive preoperative staging becomes mandatory for an adequate selection of the appropriate therapeutic concept.
  • [MeSH-minor] Algorithms. Chemotherapy, Adjuvant. Clinical Trials, Phase III as Topic. Combined Modality Therapy. Endoscopy. Esophagectomy. Esophagus / pathology. Gastrectomy. Gastric Fundus / surgery. Humans. Neoplasm Staging. Palliative Care. Prognosis. Radiotherapy, Adjuvant. Randomized Controlled Trials as Topic. Stomach / pathology. Time Factors

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11079787.001).
  • [ISSN] 0355-9521
  • [Journal-full-title] Annales chirurgiae et gynaecologiae
  • [ISO-abbreviation] Ann Chir Gynaecol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Review
  • [Publication-country] FINLAND
  • [Number-of-references] 26
  •  go-up   go-down


14. Nozoe T, Matsumata T, Sugimachi K: Serum level of C-reactive protein may be a marker for proliferation of esophageal carcinoma. Hepatogastroenterology; 2000 Nov-Dec;47(36):1622-3
MedlinePlus Health Information. consumer health - Esophageal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The patient was a 70-year-old male with advanced squamous cell carcinoma in the lower location of the esophagus, and in whom an esophagectomy and reconstruction with a gastric tube through the intrathoracic route was performed.
  • After performing chemotherapy, the concentration of the serum C-reactive protein decreased to the negative level with a simultaneous improvement in his cachexic condition and the eventual disappearance of the tumor.
  • [MeSH-major] C-Reactive Protein / metabolism. Carcinoma, Squamous Cell / blood. Carcinoma, Squamous Cell / pathology. Esophageal Neoplasms / blood. Esophageal Neoplasms / pathology. Neoplasm Recurrence, Local / blood
  • [MeSH-minor] Aged. Antineoplastic Agents / therapeutic use. Biomarkers / blood. Esophagectomy. Humans. Liver Neoplasms / blood. Liver Neoplasms / secondary. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11149017.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Biomarkers; 9007-41-4 / C-Reactive Protein
  •  go-up   go-down


15. Li AF, Hsu HS, Hsu CY, Li AC, Li WY, Liang WY, Chen JY: A 20-year retrospective study of small-cell carcinomas in Taiwan. J Surg Oncol; 2010 Oct 1;102(5):497-502
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This study aimed to examine the distribution, treatment, and survival of SCCs.
  • RESULTS: The lung (89.2%) was the most common location, followed by the esophagus (1.8%), urinary bladder (1.6%), uterine cervix (1.5%), colorectum (1.4%), skin (1.0%), stomach (0.9%), head and neck (0.7%), prostate (0.3%), and small intestine (0.1%).
  • Limited disease (LD) SCLC patients underwent surgery and chemotherapy had significantly higher survival rates than those who received chemotherapy alone, those who underwent combined radiotherapy and chemotherapy, and those who were administered supportive treatment.
  • CONCLUSION: The lung was the most common location of SCCs, with 9.3% of cases being extra-pulmonary in origin.
  • The need for combined surgery and chemotherapy in LD-SCLC patients deserves further evaluation.
  • [MeSH-minor] Aged. Aged, 80 and over. Female. Gastrointestinal Neoplasms / mortality. Gastrointestinal Neoplasms / pathology. Gastrointestinal Neoplasms / therapy. Humans. Male. Middle Aged. Neoplasm Staging. Retrospective Studies. Survival Rate. Taiwan. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] J. Surg. Oncol. 2010;102:497-502. © 2010 Wiley-Liss, Inc.
  • (PMID = 20872953.001).
  • [ISSN] 1096-9098
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


16. Chen EC, Liu MZ, Hu YH, Li QQ, Liu H, Cai L, Liu H, Lin HX, Huang Y, Wang HY, Cui NJ: [Multivariate prognostic analysis for patients with unresectable esophageal carcinoma after concurrent chemoradiotherapy]. Ai Zheng; 2005 Jun;24(6):731-4
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND & OBJECTIVE: Concurrent chemoradiotherapy is recommended as standard treatment for unresectable esophageal carcinoma now.
  • All patients received chemotherapy at the beginning of radiotherapy, and when the radiation dose escalated to 40 Gy.
  • Total dose of irradiation was 60-70 Gy.
  • Gender, age, disease course, focus location, swallow embarrassment, weight loss, Karnofsky's performance status (KPS) score, family history, hemoglobin (HB) before therapy, X-ray type, pathologic grade, focus length, TNM stage, irradiation method and technology, irradiation dose, radiotherapy interval, short-term effect, esophagus perforation, esophagus haemorrhage, and retreatment methods were used as analysis factors for Cox regression univariate and multivariate analyses.
  • RESULTS: Univariate analysis showed that diseases course, focus location, weight loss, M stage, short-term effect, esophagus perforation, esophagus haemorrhage, and retreatment methods were prognostic factors of these patients.
  • Multivariate analysis showed that M stage [P=0.014, odds ratio (OR)=2.515], short-term effect (P < 0.001, OR=2.181), esophagus perforation (P=0.022, OR=3.266), and retreatment methods (P=0.026, OR=1.142) were independent prognostic factors.
  • CONCLUSION: The main prognostic factors of the patients with unresectable esophageal carcinoma treated with concurrent chemoradiotherapy are M stage, short-term effect, esophagus perforation, and retreatment methods.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / therapy. Esophageal Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Cisplatin / administration & dosage. Combined Modality Therapy. Female. Fluorouracil / administration & dosage. Follow-Up Studies. Humans. Lymphatic Metastasis. Male. Middle Aged. Multivariate Analysis. Neoplasm Recurrence, Local. Neoplasm Staging. Prognosis. Proportional Hazards Models. Radiotherapy, High-Energy

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15946490.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


17. Swann HM, Holt DE: Canine gastric adenocarcinoma and leiomyosarcoma: a retrospective study of 21 cases (1986-1999) and literature review. J Am Anim Hosp Assoc; 2002 Mar-Apr;38(2):157-64
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This retrospective study describes the clinical course, treatment, and outcome of 21 dogs with gastric adenocarcinomas (n=19) and leiomyosarcomas (n=2).
  • Medical records from 1986 to 1999 were reviewed for signalment, weight, diagnosis, tumor location, clinical signs, radiographic imaging procedures, surgical procedures, chemotherapy, duration of follow-up monitoring, outcome, cause of death, metastatic rate, metastatic sites, and method of detection of metastasis.
  • Metastatic sites included gastric lymph nodes, omentum, liver, duodenum, pancreas, spleen, esophagus, adrenal glands, and lungs.
  • The beneficial effects of chemotherapy alone or adjuvant chemotherapy are still unknown.
  • [MeSH-minor] Animals. Antineoplastic Agents / therapeutic use. Dogs. Female. Male. Neoplasm Metastasis. Pennsylvania / epidemiology. Records as Topic / veterinary. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11908834.001).
  • [ISSN] 0587-2871
  • [Journal-full-title] Journal of the American Animal Hospital Association
  • [ISO-abbreviation] J Am Anim Hosp Assoc
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 22
  •  go-up   go-down


18. Chiewvit P, Danchaivijitr N, Sirivitmaitrie K, Chiewvit S, Thephamongkhol K: Does magnetic resonance imaging give value-added than bone scintigraphy in the detection of vertebral metastasis? J Med Assoc Thai; 2009 Jun;92(6):818-29
MedlinePlus Health Information. consumer health - MRI Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Does magnetic resonance imaging give value-added than bone scintigraphy in the detection of vertebral metastasis?
  • The MR imaging findings were studied: location (cervical or thoracic or lumbar or sacrum spine), number of lesions (solitary or multiple lesions), pattern of enhancement (homogeneous or inhomogeneous), involvement of spinal canal, compression of spinal cord, extradural extension, other incidental findings such as pulmonary metastasis, pleural effusion, lymphadenopathy The final diagnosis was confirmed clinically and followed-up for further management (radiation or surgery) or followed-up by MR imaging (1 month-16 months) and bone scintigraphy (5 months-12 months).
  • Primary neoplasms include breast cancer (n=11), colorectal cancer (n=7), lung cancer (n=6), prostate cancer (n=5), nasopharyngeal cancer (n=5), head and neck cancer (n=3), thyroid cancer (n=2), liver cancer (n=2), esophagus cancer (n=1), bladder cancer (n=1), retroperitoneum cancer (n=1), medulloblastoma (n=1), cervical cancer (n=1), ovarian cancer (n=1), malignant melanoma (n=1).
  • Furthermore, MR imaging is important for the further treatment planning such as radiation therapy or systemic chemotherapy.
  • Although MR imaging is useful in the detection of early metastasis that are localized completely in the bone marrow cavity routinely bone scintigraphy remains that most cost-effective method for examination of the entire skeleton.
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Diphosphonates. Female. Humans. Male. Middle Aged. Neoplasm Metastasis / radionuclide imaging. Organotechnetium Compounds. Radionuclide Imaging. Retrospective Studies. Spinal Cord Compression. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19530588.001).
  • [ISSN] 0125-2208
  • [Journal-full-title] Journal of the Medical Association of Thailand = Chotmaihet thangphaet
  • [ISO-abbreviation] J Med Assoc Thai
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Thailand
  • [Chemical-registry-number] 0 / Diphosphonates; 0 / Organotechnetium Compounds; 0 / technetium 99m methylene bisphosphonate
  •  go-up   go-down


19. Mornex F, Loubeyre P, Giraud P, Chapet O, Van Houtte P, Bonnette P, Sentenac I: [Gross tumor volume and clinical target volume in radiotherapy: lung cancer]. Cancer Radiother; 2001 Oct;5(5):659-70
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Radiotherapy plays a major role as a curative treatment of various stages non-small cell lung cancers (NSCLC): as an exclusive treatment in curative attempt for patients with unresectable stages I and II; as a preoperative treatment, which is often associated with chemotherapy, for patients with surgically stage IIIA NSCLC in clinical trials; in association with chemotherapy for unresectable stages IIIA and IIIB patients.
  • However, the high inherent conformality of this radiotherapy technique requires a rigorous approach and an optimal quality of the preparation throughout the treatment procedure and specifically of the accurate definition of the safety margins (GTV, CTV...).
  • Therefore the goal of radiotherapy, in this particular location, is to improve local control by increasing the dose until the maximum normal tissue tolerance is achieved, which essentially depends on the dose to the organs at risk (OAR) and specifically for the lung, the esophagus and the spinal cord.
  • 3) When radiation therapy starts after a good response to chemotherapy, the residual tumoral volume should be defined as the target volume in place of the initial tumor volume.
  • [MeSH-minor] Chemotherapy, Adjuvant. Clinical Trials as Topic. Combined Modality Therapy. Humans. Lymphatic Metastasis / radiotherapy. Neoplasm, Residual / radiotherapy. Patient Care Planning. Radiotherapy Dosage. Radiotherapy, Adjuvant

  • Genetic Alliance. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11715317.001).
  • [ISSN] 1278-3218
  • [Journal-full-title] Cancer radiothérapie : journal de la Société française de radiothérapie oncologique
  • [ISO-abbreviation] Cancer Radiother
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 50
  •  go-up   go-down


20. Wong NA, Brett L, Stewart M, Leitch A, Longley DB, Dunlop MG, Johnston PG, Lessells AM, Jodrell DI: Nuclear thymidylate synthase expression, p53 expression and 5FU response in colorectal carcinoma. Br J Cancer; 2001 Dec 14;85(12):1937-43
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Nuclear expression of TS in human tissue in vivo has not been characterised and its clinicopathological correlates in malignancy are unknown.
  • Amongst the primary carcinomas, higher TS nuclear expression was associated with prominent extracellular mucin production and right-sided location.
  • Higher TS nuclear expression also showed a significant association with poorer response to protracted venous infusional 5FU therapy.
  • There was a strong positive correlation between TS nuclear expression in primary and metastatic CRC but the latter generally showed higher expression than matched primary tumour tissue.
  • [MeSH-major] Adenocarcinoma / genetics. Antimetabolites, Antineoplastic / therapeutic use. Cell Nucleus / enzymology. Colorectal Neoplasms / genetics. Enzyme Inhibitors / therapeutic use. Fluorouracil / therapeutic use. Neoplasm Proteins / biosynthesis. Thymidylate Synthase / biosynthesis. Tumor Suppressor Protein p53 / biosynthesis
  • [MeSH-minor] Adult. Aged. Cell Differentiation. Drug Resistance, Neoplasm / genetics. Enzyme Induction. Female. Gene Expression Profiling. Genes, p53. Humans. Ki-67 Antigen / biosynthesis. Ki-67 Antigen / genetics. Male. Middle Aged. Neoplasm Metastasis. RNA, Messenger / biosynthesis. RNA, Neoplasm / biosynthesis. Reproducibility of Results. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Cancer Res. 1998 May;4(5):1227-34 [9607581.001]
  • [Cites] Eur J Cancer. 2000 May;36(8):1038-42 [10885609.001]
  • [Cites] Anticancer Res. 1998 May-Jun;18(3A):1515-20 [9673363.001]
  • [Cites] J Pathol. 1998 Jun;185(2):123-9 [9713337.001]
  • [Cites] Oncology. 1998 Nov-Dec;55(6):564-8 [9778624.001]
  • [Cites] Clin Exp Pharmacol Physiol. 1998 Nov;25(11):887-95 [9807659.001]
  • [Cites] Cell Prolif. 1998 Jun-Aug;31(3-4):113-26 [9853425.001]
  • [Cites] Mol Cell Biol. 1999 Feb;19(2):1582-94 [9891091.001]
  • [Cites] Dis Esophagus. 1998 Oct;11(4):215-20 [10071801.001]
  • [Cites] Gastroenterology. 1999 Jul;117(1):123-31 [10381918.001]
  • [Cites] J Clin Oncol. 1999 Jun;17(6):1760-70 [10561213.001]
  • [Cites] Br J Cancer. 2000 Feb;82(3):560-7 [10682666.001]
  • [Cites] Clin Cancer Res. 2000 Mar;6(3):1063-72 [10741735.001]
  • [Cites] Clin Cancer Res. 2000 Apr;6(4):1322-7 [10778957.001]
  • [Cites] Lancet. 2000 May 20;355(9217):1745-50 [10832824.001]
  • [Cites] Gastroenterology. 2000 Oct;119(4):921-8 [11040179.001]
  • [Cites] Clin Cancer Res. 2000 Dec;6(12):4797-802 [11156237.001]
  • [Cites] Br J Cancer. 2001 Mar 2;84(5):600-3 [11237378.001]
  • [Cites] Arch Pathol Lab Med. 1985 Aug;109(8):716-21 [3893381.001]
  • [Cites] Cancer Res. 1990 Jul 1;50(13):3979-84 [2162250.001]
  • [Cites] Cancer Res. 1991 Dec 15;51(24):6668-76 [1720706.001]
  • [Cites] Cancer Res. 1992 Jan 1;52(1):108-16 [1727369.001]
  • [Cites] J Biol Chem. 1994 Mar 18;269(11):8341-7 [8132557.001]
  • [Cites] J Clin Oncol. 1994 Oct;12(10):2035-42 [7931471.001]
  • [Cites] J Clin Oncol. 1994 Dec;12(12):2640-7 [7989939.001]
  • [Cites] Cancer Res. 1995 Apr 1;55(7):1407-12 [7882343.001]
  • [Cites] Eur J Cancer. 1995 Jul-Aug;31A(7-8):1101-4 [7577000.001]
  • [Cites] Eur J Cancer. 1995 Jul-Aug;31A(7-8):1299-305 [7577040.001]
  • [Cites] Eur J Cancer. 1995 Jul-Aug;31A(7-8):1306-10 [7577041.001]
  • [Cites] Eur J Surg Oncol. 1996 Apr;22(2):182-5 [8608838.001]
  • [Cites] Nucleic Acids Res. 1996 Aug 15;24(16):3222-8 [8774904.001]
  • [Cites] Br J Cancer. 1997;75(6):903-9 [9062414.001]
  • [Cites] J Biol Chem. 1997 May 16;272(20):13281-5 [9148948.001]
  • [Cites] Exp Cell Res. 1997 Aug 1;234(2):270-6 [9260894.001]
  • [Cites] Int J Cancer. 1997 Sep 17;72(6):1137-41 [9378551.001]
  • [Cites] Cancer. 1998 Jan 1;82(1):70-7 [9428481.001]
  • [Cites] Eur J Cancer. 1997 Nov;33(13):2278-81 [9470819.001]
  • [Cites] Clin Cancer Res. 1998 May;4(5):1243-50 [9607583.001]
  • (PMID = 11747337.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Scotland
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Enzyme Inhibitors; 0 / Ki-67 Antigen; 0 / Neoplasm Proteins; 0 / RNA, Messenger; 0 / RNA, Neoplasm; 0 / Tumor Suppressor Protein p53; EC 2.1.1.45 / Thymidylate Synthase; U3P01618RT / Fluorouracil
  • [Other-IDs] NLM/ PMC2364004
  •  go-up   go-down


21. Liao Z, Zhang Z, Jin J, Ajani JA, Swisher SG, Stevens CW, Ho L, Smythe R, Vaporciyan AA, Putnam JB Jr, Walsh GL, Roth JA, Yao JC, Allen PK, Cox JD, Komaki R: Esophagectomy after concurrent chemoradiotherapy improves locoregional control in clinical stage II or III esophageal cancer patients. Int J Radiat Oncol Biol Phys; 2004 Dec 1;60(5):1484-93
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: To evaluate the effect of surgical resection on the outcome of patients with clinical Stage II or III cancer of the esophagus treated with concurrent chemoradiotherapy.
  • The median radiation dose was 50 Gy (range, 30-64.8 Gy) in the definitive chemoradiation group and 45 Gy (range, 30-50.4 Gy) in the chemoradiation plus esophagectomy group.
  • RESULTS: Statistically significant differences were found between the two groups in median age, histologic subtype, tumor location, and number of patients with T4 disease.
  • Patients who underwent definitive chemoradiotherapy were older (p = 0.0004) and more likely to have squamous cell carcinoma than adenocarcinoma (p <0.000), upper thoracic or cervical esophageal tumors (p <0.000), and T4 tumors (p = 0.024).
  • Patients treated with chemoradiation plus esophagectomy had statistically significant superior 5-year loco-regional control (67.1% vs. 22.1%, p <0.000), disease-free survival (40.7% vs. 9.9%, p < 0.000), and 5-year overall survival (52.6% vs. 6.5%, p < 0.000) rates and median survival time (62 vs. 12 months) compared with patients treated with chemoradiotherapy only.
  • The results from this study suggest the need for a randomized trial to compare chemoradiation with or without esophagectomy in the treatment of cancer of the esophagus.
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / pathology. Adenocarcinoma / radiotherapy. Adenocarcinoma / surgery. Adult. Aged. Aged, 80 and over. Analysis of Variance. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cisplatin / administration & dosage. Combined Modality Therapy. Female. Fluorouracil / administration & dosage. Humans. Male. Middle Aged. Neoplasm Staging. Radiotherapy Dosage. Retrospective Studies. Treatment Failure

  • Genetic Alliance. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15590179.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down






Advertisement